Wave Life Sciences Ltd. (WVE)

NGM – Real Time Price. Currency in USD

6.79

-0.28 (-3.96%)

At close: May 12, 2026, 4:00 PM EDT

7.00

+0.21 (3.09%)

Pre-market: May 13, 2026, 9:03 AM EDT

28.04.2026

Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.29 per share a year ago.

28.04.2026

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track to initiate in 2Q 2026

22.04.2026

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, April 28, 2026, to review the company's first quarter 2026 financial results and provide business updates.

21.04.2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, is seeking shareholders' and Singapore High Court approvals in relation to a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”), in order to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States (the “Redomiciliation”).

15.04.2026

Wave Life Sciences Announces Proposed Redomiciliation to the United States

CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that its board of directors has unanimously approved a plan to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States (the Redomiciliation).

01.04.2026

Is This Weight Loss Drug Stock a Buy on the Dip?

Wave Life Sciences' shares dropped after its weight loss candidate failed to impress in a phase 1 study. However, this product could actually be successful if it can confirm its recent phase 1 results.

01.04.2026

Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Videos

No Data

There is no data to display

Press releases

28.04.2026

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

22.04.2026

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

21.04.2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

15.04.2026

Wave Life Sciences Ltd. (WVE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Wave Life Sciences Ltd. (WVE)

Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Is This Weight Loss Drug Stock a Buy on the Dip?

Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?

Videos

No Data

Press releases

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Is This Weight Loss Drug Stock a Buy on the Dip?

Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?

Videos

No Data

Press releases

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Search stocks

Wave Life Sciences Ltd. (WVE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Wave Life Sciences Ltd. (WVE)

Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Is This Weight Loss Drug Stock a Buy on the Dip?

Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?

Videos

No Data

Press releases

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Is This Weight Loss Drug Stock a Buy on the Dip?

Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?

Videos

No Data

Press releases

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States